deltatrials
Completed PHASE1 NCT00001676

Cyclophosphamide and Fludarabine to Treat Lupus Nephritis

Combination of Cyclophosphamide and Fludarabine for Lupus Nephritis: Tolerance, Toxicity, Efficacy and Effects on B and T Lymphocyte Regeneration

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Conditions Glomerulonephritis Lupus Nephritis Systemic Lupus Erythematosus
Interventions SQ Fludarabine
Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Jan 31, 1998 Completion: Nov 30, 2002

Listed as NCT00001676, this PHASE1 trial focuses on Glomerulonephritis and Lupus Nephritis and remains completed. Sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), it has been updated 5 times since 1998, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Jan 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States